John M. Kane III, MD, FACS
John M. Kane III, MD, FACS
I am an Associate Professor of Surgery and Chief of the Melanoma/Sarcoma service at Roswell Park Cancer Institute (RPCI). My interest in melanoma, sarcoma, and regional therapies dates back to the beginning of my practice in the year 2000. I am the main sarcoma surgeon at RPCI and treat soft tissue sarcomas at all anatomic locations; extremity, truncal, intra-abdominal/retroperitoneal, head and neck, and gastrointestinal stromal tumors (GIST). I am a member of major sarcoma groups including the NCCN Sarcoma Panel, the Connective Tissue Oncology Society, and the Radiation Therapy Oncology Group (RTOG) Sarcoma Committee. I have been the lead investigator for several sarcoma trials at RPCI, have authored multiple papers on the treatment of soft tissue sarcomas, and have been an invited speaker on this topic at national meetings. I oversee our weekly sarcoma/soft tissue tumor multidisciplinary conference where all new sarcoma and rare soft tissue tumor cases are discussed in order to develop the optimal treatment plan.
I also treat unusual benign and locally aggressive soft tissue tumors. These include desmoid/aggressive fibromatosis, dermatofibrosarcoma protuberans (DFSP), neurogenic tumors such as neurofibroma and schwannoma, large and atypical intramuscular lipomatous tumors, solitary fibrous tumor, ganglioneuroma, and adrenal myelolipoma. As noted above, our weekly multidisciplinary conference allows for a thorough discussion of the patients with these various tumors. In some cases, surgery may not even be necessary.
I have a significant clinical interest in melanoma and other aggressive cutaneous malignancies such as Merkel cell carcinoma. Our Institution has been offering sentinel lymph node biopsy since 1996 and I have personally performed over 450. For patients with nodal metastatic disease, I frequently perform axillary dissections (very different from what is done for breast cancer), superficial and deep groin dissections, and even less common lymphadenectomies in the epitrochlear and popliteal basins. I have advanced the regional therapies program at RPCI for patients with isolated extremity disease (in transit melanoma, Merkel cell carcinoma, and some sarcomas) that is no longer amenable to simple surgical excision. Isolated limb perfusion (ILP) or isolated limb infusion (ILI) can still be potentially curative in these situations. Roswell Park Cancer Institute is one of only two institutions in New York State that performs these isolated regional therapies.
As another type of isolated regional therapy, I developed the cytoreduction/hyperthermic intraperitoneal chemoperfusion (HIPEC) program at RPCI in 2002. I routinely perform cytoreductive surgery/HIPEC for appendiceal neoplasms, colorectal cancer, mesothelioma, and other peritoneal surface malignancies. In addition to patients with these diseases in WNY, I have provided this treatment option for the province of Ontario.
Aside from my clinical responsibilities, I serve as the Surgical Oncology Fellowship Program Director and on the Executive Council of the Society of Surgical Oncology. I am a fellow of the American College of Surgeons and a member of multiple surgical and oncologic societies, including the Society of Surgical Oncology, the American Society of Clinical Oncology, and the Association for Academic Surgeons. I have served as the past president for both the WNY Chapter of the American College of Surgeons and the Buffalo Surgical Society. I was also previously the WNY State Chair for the ACS Commission on Cancer.
- Nurkin SJ, Kane JM 3rd. Margin status, local recurrence, and survival: correlation or causation?. Surgical oncology clinics of North America 2012; 212:255-267
- Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Annals of surgical oncology 2012; 194:1074-1080
- Kane JM 3rd, Harris J, Kraybill WG, Harmon DC, Ettinger DS, Lucas DR, Delaney TF, Wang D, Curran WJ, Eisenberg BL. Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330. Sarcoma 2012; 2012 :659485
- Qian J, Yi H, Guo C, Yu X, Zuo D, Chen X, Kane III JM, Repasky EA, Subjeck JR, Wang X-Y. CD204 suppresses large heat shock protein-facilitated priming of tumor antigen gp100-specific T cells and chaperone vaccine activity against mouse melanoma. Journal of immunology (Baltimore, Md. : 1950) 2011;1876:2905-2914
- Zeitouni NC, Giordano CN, Kane JM. In-transit merkel cell carcinoma treated with isolated limb perfusion or isolated limb infusion: a case series of 12 patients. Dermatologic surgery 2011; 373:357-364
- Turaga KK, Tyler DS, Cheong D, Letson GD, Gonzalez RJ, Grobmyer SR, Delman KA, Kane III JM, Beasley GM, Zager JS. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. Archives of surgery (Chicago, Ill. : 1960) 2011;1467:870-875
- Meguerditchian AN, Asubonteng K, Young C, Lema B, Wilding G, Kane JM 3rd. Thick primary melanoma has a heterogeneous tumor biology: an institutional series. World journal of surgical oncology 2011;9:40
- Ito F, Camoriano M, Seshadri M, Evans SS, Kane JM 3rd, Skitzki JJ. Water: a simple solution for tumor spillage. Annals of surgical oncology 2011; 188:2357-2363
- Najarian DJ, Morrison C, Sait SNJ, Meguerditchian AN, Kane III J, Cheney R, Zeitouni NC. Recurrent giant cell fibroblastoma treated with Mohs micrographic surgery. Dermatologic surgery 2010; 363:417-421
- Demetri GD, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, Von Mehren M, McGarry SV, Letson GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad III EU, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane III JM, Wayne J. Soft tissue sarcoma. Journal of the National Comprehensive Cancer Network : JNCCN 2010; 86:630-674
- Wang XY, Sun X, Chen X, Facciponte J, Repasky EA, Kane J, Subjeck JR. Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen. Journal of immunology (Baltimore, Md. : 1950) 2010; 18411:6309-6319
- Meguerditchian A-N, Wang J, Lema B, Kraybill WG, Zeitouni NC, Kane JM. Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. American journal of clinical oncology 2010; 333:300-303
- Beasley GM, Ross MI, Pruitt SK, Seigler H, Kane JM, Noyes RD, Andtbacka RH, Delman KA, Grobmyer SR, Hochwald SN, Zager JS, Mosca PJ, Padussis J, McMahon NS, Petersen RP, Caudle A, Tyler DS. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. Journal of the American College of Surgeons 2009; 2085:706-715; discussion 715-7
- Smith R, Pak Y, Kraybill W, Kane JM. Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy. European journal of surgical oncology 2009; 354:356-361
- Meguerditchian A-N, Cheney RT, Kane III JM. Nevus spilus with synchronous melanomas: case report and literature review. Journal of cutaneous medicine and surgery 2009; 132:96-101
- Eisenberg BL, Kane JM, Okuno S, Hoffman JP, Watson JC, Heinrich MC, Demetri GD, Blanke CD, Harris J, Von Mehren M. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. Journal of surgical oncology 2009; 991:42-47
- Santillan AA, Tyler DS, Ross MI, Kane JM, Noyes RD, Andtbacka RH, Grobmyer SR, Hochwald SN, Mosca PJ, Beasley GM, Delman KA, Zager JS. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Annals of surgical oncology 2009; 169:2570-2578
- Agrawal S, Kane JM, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009; 11524:5836-5844
- Samie FH, Kane JM 3rd, Zeitouni NC. Repair of large abdominal defects with prostheses following Mohs micrographic surgery: case series and review of literature. Dermatologic surgery 2008; 343:403-406
- Society of Surgical Oncology Annual Meeting, Riley L, Quinones M, Piso P, Pitroff A, Pingpank J, Philippe G, Petrelli N, Onate-Ocana L, Morris D, Moran B, Misih RA, Martin R, Mann G, Mahteme H, Loggie B, Li B, Lange J, Rutstein L, Saha S, Sebbag G, Zoetmulder F, Zeh H, Younan R, Wilkinson N, Villar J, Verwaal V, Tuttle T, Torres-Melero J, Stewart J, Stojadinovic A, Spellman J, Shibata D, Shen P, Schneebaum S, Sardi A, Alrawi S, Lamont J, Kuhn J, Deraco M, de Bree E, Daniel S, Chu Q, Chu F, Chang CK, Bretcha-Boix P, Bieligk S, Barrios P, Barone R, Bartlett D, Baratti D, Alexander R, Yan TD, Levine E, Sugarbaker P, Sticca R, Dominguez-Parra L, Elias D, Kelley S, Kecmanovic D, Kane J, Hoefer R, Harrison L, Hartmann J, Hanna N, Gushchin V, Goodman M, Gonzalez-Moreno S, Gonzalez-Bayon L, Gomez-Portilla A, Glehen O, Gilly FN, Garofalo A, Foster J, Flynn R, Esquivel J. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Annals of surgical oncology 2007; 141:128-133
- Gushchin V, Demmy TL, Kane JM 3rd. Surgical management of metastatic peritoneal or pleural disease.Seminars in oncology 2007; 343:215-225